Therapy landscape in patients with metastatic HER2-positive breast cancer: Data from the PRAEGNANT real-world breast cancer registry

Journal article


Publication Details

Author(s): Lux MP, Nabieva N, Hartkopf AD, Huober J, Volz B, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lueftner D, Wallwiener M, Mueller V, Beckmann M, Belleville E, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm TN, Wallwiener D, Schneeweiss A, Brucker SY
Journal: Cancers
Publication year: 2019
Volume: 11
Journal issue: 1
ISSN: 2072-6694


Abstract

This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns with trastuzumab (H), pertuzumab + trastuzumab (PH), lapatinib (L), and trastuzumab emtansine (T-DM1). The PRAEGNANT study is a real-time, real-world registry for MBC patients. All therapy lines are documented. This analysis describes the utilization of anti-HER2 therapies as well as therapy sequences. Among 1936 patients in PRAEGNANT, 451 were HER2-positive (23.3%). In the analysis set (417 patients), 53% of whom were included in PRAEGNANT in the first-line setting, 241 were treated with H, 237 with PH, 85 with L, and 125 with T-DM1 during the course of their therapies. The sequence PH ! T-DM1 was administered in 51 patients. Higher Eastern Cooperative Oncology Group (ECOG) scores, negative hormone receptor status, and visceral or brain metastases were associated with more frequent use of this therapy sequence. Most patients received T-DM1 after treatment with pertuzumab. Both novel therapies (PH and T-DM1) are utilized in a high proportion of HER2-positive breast cancer patients. As most patients receive T-DM1 after PH, real-world data may help to clarify whether the efficacy of this sequence is similar to that in the approval study.


FAU Authors / FAU Editors

Beckmann, Matthias Prof. Dr.
Lehrstuhl für Geburtshilfe und Frauenheilkunde
Fasching, Peter PD Dr.
Professur für Translationale Frauenheilkunde und Geburtshilfe
Nabieva, Naiba Dr. med.
Frauenklinik


External institutions with authors

Centrum für Hämatologie und Onkologie Bethanien
Charité - Universitätsmedizin Berlin
ClinSol GmbH & Co.KG
Eberhard Karls Universität Tübingen
Gynäkologie Kompetenzzentrum Stralsund: gSUND
HELIOS Kliniken
Klinikum der Universität München
Krankenhaus Nordwest
Marienhospital Bottrop
Martin-Luther-Universität Halle-Wittenberg (MLU)
Medizinisches Versorgungszentrum Medizin Center Bonn
Oncologianova GmbH
Praxisklinik am Rosengarten
Ruprecht-Karls-Universität Heidelberg
Technische Universität München (TUM)
Universitätsklinikum Carl Gustav Carus Dresden
Universitätsklinikum Düsseldorf
Universitätsklinikum Hamburg-Eppendorf
Universitätsklinikum Ulm


How to cite

APA:
Lux, M.P., Nabieva, N., Hartkopf, A.D., Huober, J., Volz, B., Taran, F.-A.,... Brucker, S.Y. (2019). Therapy landscape in patients with metastatic HER2-positive breast cancer: Data from the PRAEGNANT real-world breast cancer registry. Cancers, 11(1). https://dx.doi.org/10.3390/cancers11010010

MLA:
Lux, Michael P., et al. "Therapy landscape in patients with metastatic HER2-positive breast cancer: Data from the PRAEGNANT real-world breast cancer registry." Cancers 11.1 (2019).

BibTeX: 

Last updated on 2019-23-05 at 15:08